A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia

Camila Nascimento^{a*}, Paula Villela Nunes^a, Roberta Diehl Rodriguez^b, Leonel Takada^c, Cláudia Kimie Suemoto^d, Lea Tenenholz Grinberg^{e,f}, Ricardo Nitrini^c, Beny Lafer^a

- a. Bipolar Disorder Program (PROMAN), Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil
(camisnascimento@usp.br, paula@formato.com.br, blafer@usp.br)
- b. Behavioral and Cognitive Neurology Unit, Department of Neurology and LIM 22, University of São Paulo, São Paulo, 05403-900, Brazil
(robertadiehlr@gmail.com)
- c. Behavioral and Cognitive Neurology Unit, Department of Neurology, University of São Paulo, São Paulo, 05403-900, Brazil
(leonel.takada@gmail.com, rnrtrini@uol.com.br)
- d. Division of Geriatrics, LIM-22, University of São Paulo Medical School, São Paulo, 01246-90, Brazil (csuemoto@gmail.com)
- e. Department of Pathology, LIM-22, University of São Paulo Medical School, São Paulo, 01246-90, Brazil (Lea.Grinberg@ucsf.edu)
- f. Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, 94143-120, USA
(Lea.Grinberg@ucsf.edu)

Corresponding author:

Camila Nascimento

785, Doutor Ovídio Pires de Campos Street

Telephone: +55 11 2661 7928

São Paulo, SP, Brazil

E-mail: camisnascimento@usp.br

Abstract

Mental disorders are highly prevalent and important causes of medical burden worldwide. Co-occurrence of neurological and psychiatric symptoms are observed among mental disorders, representing a challenge for their differential diagnosis. Psychiatrists and neurologists have faced challenges in diagnosing older adults presenting behavioral changes. This is the case for early frontotemporal dementia (FTD) and late bipolar disorder. Early FTD is characterized by behavioral or language disturbances in the absence of cognitive symptoms. Consequently, patients with the behavioral subtype of FTD (bv-FTD) can be initially misdiagnosed as having a psychiatric disorder, typically depression or bipolar disorder (BD). Bipolar disorder is associated with a higher risk of dementia in older adults and cognitive impairment, where a subset of patients presents a neuroprogressive pattern during the disease course. Clinical similarities between BD and bv-FTD raise the question whether common molecular pathways might explain shared clinical symptoms. In fact, studies have also shown presence of molecular signatures related to bv-FTD in BD patients. Here, we reviewed existing data on clinical and molecular similarities between BD and FTD and propose biological pathways to be further investigated as common or specific markers of BD and FTD.

Keywords: bipolar disorder; frontotemporal dementia; neuropsychiatric symptoms; neurodegeneration; biomarkers

Contents

1. Introduction
2. Clinical symptoms of bipolar disorder relevant to neurology
 - 2.1 Clinical features and cognitive impairment in bipolar disorder
 - 2.2 Neuropathology in bipolar disorder
3. Clinical symptoms of frontotemporal dementia relevant to psychiatry
4. Clinical aspects common to bipolar disorder and frontotemporal dementia
 - 4.1 Differential diagnosis of bipolar disorder and frontotemporal dementia
5. Biological aspects of bipolar disorder and frontotemporal dementia
 - 5.1 Neuropathology of frontotemporal dementia
 - 5.2 Neuropathology of bipolar disorder
 - 5.3 Molecular genetic studies in frontotemporal dementia
 - 5.4 Molecular genetic studies in bipolar disorder
 - 5.5 Molecular genetic findings common to bipolar disorder and frontotemporal dementia
6. Shared biological pathways may underlie both bipolar disorder and frontotemporal dementia
7. Hypothetical model of molecular mechanisms shared by bipolar disorder and frontotemporal dementia

1. Introduction

The World Health Organization estimates that approximately 15% of adults worldwide aged 60 years or over currently suffer from some form of mental disorder (WHO, 2018). Data from the same source show that mental disorders are responsible for 6.6% of all disability (disability-adjusted life years - DALYs) in this age group. Dementia and depression are the most common forms of mental and neurological disorders in the elderly. With the older population growing rapidly (Alzheimer's, 2016), physical and mental health challenges will need to be recognized. Unfortunately, mental health issues are still under-identified by older subjects and their family members, as well as by healthcare professionals (Alzheimer's, 2016; WHO, 2018). There is also a stigma attached to these conditions, which makes sufferers reluctant to seek medical care. Even when receiving medical care, challenges remain concerning diagnosis and treatment, since neurological and psychiatric symptoms can co-occur in the same patient (Choi et al., 2017; Woolley et al., 2011).

Co-occurrence of cognitive and psychiatric symptoms in the elderly is an issue not only in the case of Alzheimer's disease (AD) (Lanctot et al., 2017), but also in more recently recognized types of dementia. In frontotemporal dementia (FTD), for instance, behavioral or language disturbances can manifest in the absence of cognitive symptoms at early stages of the disease (Chare et al., 2014; Liscic et al., 2007; Mendez et al., 2007; Miller et al., 1995; Nyatsanza et al., 2003; Woolley et al., 2011; Woolley et al., 2007; Zamboni et al., 2008). Patients with the behavioral subtype of FTD (bv-FTD) are initially diagnosed with a psychiatric condition significantly more often than patients with AD or other FTD subtypes (Woolley et al., 2011). Furthermore, bv-FTD

patients were more likely to be misdiagnosed as having major depressive disorder (MDD), bipolar disorder (BD) or schizophrenia (SQZ). Interestingly, BD is associated with a significantly higher risk of dementia in older adults (Diniz et al., 2017), and cognitive impairments have been consistently found in this disorder (Cullen et al., 2016). Moreover, the course of BD may follow a progressive pattern, as observed in a subgroup of patients (Bauer et al., 2017; Kapczinski et al., 2014; Magalhaes et al., 2012). This progression includes the presence of cognitive impairment later in the disease course (Elshahawi et al., 2011; Martinez-Aran et al., 2004), a feature also characteristic of bv-FTD (Chare et al., 2014).

Clinical similarities between BD and bv-FTD have been a focus of research in the past decade (Dols et al., 2016; Kerstein et al., 2013; Lopes and Fernandes, 2012; Masouy et al., 2011; Rubino et al., 2017; Woolley et al., 2011; Woolley et al., 2007), raising the question whether the same molecular pathways might explain shared clinical symptoms. The presence of different misfolded proteins in the brain, as well as genetic mutations (associated with these misfolded proteins or otherwise), are hallmarks in the pathology of FTD (Lowe, 2011; Mackenzie and Neumann, 2016; Takada, 2015, 2017). In addition, other molecular pathways, such as inflammation, neuroprotection and oxidative stress, have been further investigated in BD (Muneer, 2016). Here, we reviewed the existing data on clinical and molecular similarities between BD and FTD (with a focus on bv-FTD whenever possible) to propose potential biological pathways that can be further investigated as common or specific markers of BD and FTD. Our knowledge related to specific biomarkers of neurological and psychiatric conditions is still limited.

Unrevealing specific biological pathways related to FTD and BD enables us to better understand the pathophysiology of these diseases, and thus, improving diagnostic tools for differential diagnosis.

2. Clinical symptoms of bipolar disorder relevant to neurology

2.1 Clinical features and cognitive impairment in bipolar disorder

Bipolar disorder is characterized by recurrent episodes of mania and depression, interspersed with periods of normal mood, energy and behavior (euthymia). During manic episodes, patients experience racing thoughts, disinhibition, impulsivity, elevated mood, grandiosity and low need for sleep, while episodes of depression are characterized by sadness, thoughts of guilt, and incapacity to feel pleasure or interest in daily activities (anhedonia). Additionally, some degree of cognitive impairment can often be found in patients with BD, even during euthymia (Burdick et al., 2010).

Although cognitive impairments are present in various psychiatric disorders, they can be especially prominent in BD (Cullen et al., 2017; Vohringer et al., 2013). The trajectory of BD can be highly variable, and progressive worsening of cognitive functions can occur in a subgroup of these patients (Burdick et al., 2015; Van Rheenen et al., 2017). In a meta-analysis, different rates of impairment in multiple cognitive domains of euthymic BD patients were found in cross-sectional studies: executive function 5.3-57.7%, attention/working memory 9.6-51.9%, speed/reaction time 23.3-44.2%, verbal memory 8.2-42.1% and visual memory 11.5-32.9% (Cullen et al., 2016). The high prevalence and evidence of impairments in multiple cognitive domains suggest cognitive decline is an endophenotype of at least a subgroup of BD patients. Trait-related cognitive deficits are present at BD onset and become

more severe at later stages of the disease (Rosa et al., 2014). Meta-analytical data on cognitive impairment among non-demented patients in remission from acute episodes of BD showed that executive and verbal memory were the most commonly impaired domains (Balanza-Martinez et al., 2010). Recent studies have demonstrated that executive function, working memory, and verbal memory are the domains especially affected in BD patients (Bourne et al., 2013; Ospina et al., 2018; Vrabie et al., 2015). Memory impairment could explain functional problems in patients, even during euthymic periods (Cullen et al., 2016; Mann-Wrobel et al., 2011; Martinez-Aran et al., 2004). Several studies have shown that BD patients may exhibit cognitive decline during the disease course. However, these results vary with regard to the cognitive domains affected, as well as the associated risk factors (Arts et al., 2008; Bora et al., 2009; Cullen et al., 2017; Gildengers et al., 2007). The number of manic episodes seems to be the clinical marker most strongly associated with neuroprogression in BD, as described in recent reviews (Passos et al., 2016). Other reviews involving adults associated greater cognitive impairment with more severe or longstanding illness and with use of antipsychotic medication (Cullen et al., 2016). A meta-analysis including data from 31 studies and 2876 subjects showed that BD patients had impairments in all cognitive domains evaluated (executive function, attention, verbal memory, and learning and response inhibition), even after adjusting for confounding factors, such as age, gender and IQ (Bourne et al., 2013).

The presence of cognitive dysfunction is particularly noteworthy given the evidence that some patients with BD start out cognitively intact or even with superior cognitive functioning relative to healthy controls (MacCabe et al.,

2010). However, more recent data collected through systematic review and meta-analysis indicate that cognitive deficits can be present in early stages of BD (Daglas et al., 2015; Lee et al., 2014). A meta-analysis on cognitive performance in first-episode BD (any phase: depression, hypomania, mania, mixed or psychosis), indicated deficits with small to large effects for processing speed, attention, verbal learning, memory and executive functions compared to healthy controls (Lee et al., 2014). A systematic review of cognitive functioning in the early stages of BD showed deficits in working memory as the most consistent finding (Daglas et al., 2015). Further longitudinal studies may help elucidate the longitudinal trajectory of cognitive impairment from first-episode.

BD in older adults is associated with increased risk of dementia over the long-term (Diniz et al., 2017; Rise et al., 2016). This finding appears to be correlated with the number of major affective episodes throughout the clinical course of the disease, particularly those requiring hospitalization (Kessing and Andersen, 2004). However, data on the cognitive profile of older adults with BD that develop dementia is scarce. The e4 allele of apolipoprotein E (APOE*4) is a well-established risk factor for dementia in AD. APOE*4 was not associated with BD diagnosis and appeared not to impact the occurrence of dementia in BD (Kerr et al., 2016). Also, cognitively impaired patients with BD do not display the so-called AD bio-signature in cerebrospinal fluid (CSF - i.e., low beta-amyloid and high hyperphosphorylated tau protein levels). Given the distinct clinical and biological features of cognitive impairment in BD, dementia in BD seems to be unrelated to AD pathological mechanisms (Kerr et al., 2016). Cognitive deterioration in BD is not associated with the classical

pathophysiological mechanisms observed in AD (Forlenza et al., 2016). Many possible mechanisms may underlie the cognitive deficits in older adults with BD, such as residual mood symptoms, structural brain abnormalities, long-term side effects of medications and adverse psychosocial conditions. Additionally, medical comorbidities, such as diabetes, can also contribute to this scenario (Aprahamian et al., 2014; Hajek et al., 2014), although this issue has yet to be fully elucidated. For example, subjects with late-stage BD had decreased hippocampal volume and worse verbal memory recall, but no correlation between these two variables was found (Cao et al., 2016). As mentioned above, further longitudinal research on cognitive performance after the onset of BD is needed to determine the extent to which cognitive deficits progress over time (Daglas et al., 2015). In a five-year follow-up of older adults, the group with BD exhibited worse cognitive performance in comparison to healthy older subjects at baseline, but did not have greater cognitive decline during follow-up. Interestingly, subclinical manic symptoms at baseline predicted a decline in memory (Schouws et al., 2016). Similar results were found in a 9-year follow-up of bipolar euthymic patients at baseline and during follow-up. Cognitive impairment remained stable over several clinical evaluations, except for a worsening of executive function, which was associated with disease duration and with subsyndromal depressive symptoms (Torrent et al., 2012).

2.2 Neuropression in bipolar disorder

Considering the cognitive impairments observed in a subset of BD patients, different authors have proposed that the clinical course of BD may follow a progressive path (Duffy et al., 2014; Muneer, 2016). Other clinical

findings, such as higher number of spontaneous mood episodes and hospitalizations, increased risk of suicide, and poor response to treatment during the disease course corroborate the neuroprogressive hypothesis of the disease (Passos et al., 2016; Tidemalm et al., 2014). Biological findings have also corroborated this hypothesis through neuroimaging, as well as neurocognitive studies (Bora et al., 2010; Lin et al., 2013). For example, bipolar patients with poor clinical evolution were found to have worse cognitive performance and smaller hippocampal volumes than subjects with better outcomes (Cao et al., 2016). Both clinical and biological factors have indicated the progressive nature of BD. The concept of neuroprogression postulates that different mood episodes could promote cumulative damage in neural cells (neurons and glia), affecting their neural activity, and ultimately, causing brain vulnerability to subsequent episodes (Vieta et al., 2013). This process involves dysfunctions in several systems, potentially affecting cellular resilience and neural plasticity (Berk et al., 2011; Grande et al., 2016; Vavakova et al., 2015). This vulnerability seems to be related to increased inflammation, where cytokines seem to play a role, as well as a number of modifications caused by increased oxidative stress, mitochondrial dysfunction and a decrease in neurotropic factors (Cunha et al., 2006; Fernandes et al., 2011; Gigante et al., 2011; Kapczinski et al., 2010; Kapczinski et al., 2008; Nery et al., 2016). The concept of neuroprogression in BD also reflects neurodegeneration in these patients. This raises the question whether the clinical similarities between BD and early FTD could be underpinned by specific alterations in the cognitive network and at molecular levels.

3. Clinical symptoms of frontotemporal dementia relevant to psychiatry

Unlike other types of dementia, such as AD, cognitive decline is not a hallmark symptom in the early stages of FTD. The term frontotemporal dementia includes different clinical syndromes preferentially affecting the frontal and temporal lobes. For this reason, the term encompasses heterogeneous clinical syndromes. According to the prevalence of symptoms at earlier stages, FTD is divided into three different clinical subtypes: behavioral variant, semantic variant, and non-fluent progressive aphasia (Gorno-Tempini et al., 2011; McKhann et al., 2001b). In all clinical subtypes, cognitive decline typically occurs at more advanced stages, while behavioral or language disturbances are the first symptoms to manifest (Chare et al., 2014; Liscic et al., 2007).

The most common form of FTD is the behavioral subtype (bv-FTD). This form is highly relevant to psychiatry, since early bv-FTD symptoms overlap with primary psychiatric disorders. Several behavioral and personality changes observed in BD patients during manic episodes are also observed in bv-FTD, such as changes in dietary habits, loss of social awareness, disinhibition, and stereotypical behaviors (Mendez et al., 2007; Miller et al., 1995; Nyatsanza et al., 2003; Zamboni et al., 2008).

Psychosis is a psychiatric symptom seen in FTD patients that has attracted increased attention in the past few years. In a review, the prevalence of psychosis in FTD patients reached as high as 50% of cases (Hall and Finger, 2015). In addition, delusion was found in 25% of the patients in large case series (Leger and Banks, 2014; Schoder et al., 2010). In the biggest

case series of neuropathologically-confirmed FTD patients (n=97), 32% exhibited psychotic symptoms (21% with delusions and 18% with hallucinations) (Landqvist Waldo et al., 2013). Further studies involving large case series should be performed to better characterize the most frequent types of psychiatric symptoms in FTD patients.

4. Clinical aspects common to bipolar disorder and frontotemporal dementia

The neuroprogression of BD seen in a subset of cases is characterized essentially by the presence of recognized mood swings at all stages of the disease, and also cognitive decline that, although sometimes present initially, are more pronounced in advanced stages. A similar clinical picture is observed in FTD. Thus, increasing research in the field has highlighted clinical characteristics common to BD and dementia, and to FTD and psychiatric disorders (Dols et al., 2016; Kerstein et al., 2013; Lopes and Fernandes, 2012; Masouy et al., 2011; Rubino et al., 2017; Woolley et al., 2007). Review studies have investigated the clinical similarities between FTD and BD (Lopes and Fernandes, 2012; Masouy et al., 2011), as have case reports (Kerstein et al., 2013; Rubino et al., 2017; Woolley et al., 2007) and case series (Dols et al., 2016), all published by independent groups. Generally, case report studies present the clinical history of FTD patients initially misdiagnosed with late-onset BD based on predominant behavioral changes consistent with manic episodes. However, clinical follow-up, in addition to neuroimaging findings showing severe degeneration of the pre-frontal lobe, led to a change in final diagnosis to FTD (Kerstein et al., 2013; Woolley et al., 2007). One case report, for instance, described a patient with late-onset BD subsequently

diagnosed as having bv-FTD (Rubino et al., 2017). This patient also had a mutation in the progranulin gene (GRN), a type of monogenic cause of bv-FTD. On the other hand, the case series reported four BD cases that gradually developed into a clinical syndrome, including apathy, disinhibition, loss of empathy, stereotypical behavior, and compulsiveness, fulfilling criteria for possible bv-FTD. These cases were followed up for 10 years and, unexpectedly, imaging findings showed no evidence of severe neurodegeneration. These results suggest that bv-FTD symptoms may also be present in end-stage BD, making differential diagnosis difficult in specific cases. Evidence from original articles also supports the clinical overlap between BD and FTD. A number of findings show that bv-FTD cases were initially misdiagnosed as BD, major depression disorder (MDD) and other psychoses (Kerstein et al., 2013; McKhann et al., 2001a; Mendez et al., 2007; Passant et al., 2005; Woolley et al., 2011). A systematic retrospective blinded chart review showed that 51% of bv-FTD patients had received an initial diagnosis of mood disorder. The most frequent diagnosis was MDD (60% of cases), followed by BD (18% of cases) (Woolley et al., 2011). We can speculate that, in the initial stages of FTD and BD, similar molecular, cellular, and possibly network dysfunctions may be pivotal in the development of clinical manifestations. Hypoconnectivity of the salience network, particularly in the frontoinsular and anterior cingulate cortex, is well established in the early stages of bv-FTD (Seeley, 2017). In BD, however, the evidence of salience network dysfunction is limited. A recent systematic review found no differences in resting state functional connectivity in the salience network between euthymic BD patients and controls, but the phenomenon has been

less studied in maniac and depressive episodes (Syan et al., 2018).

Nonetheless, regions in the medial prefrontal regions (including the insula and anterior cingulate cortex) – also part of the salience network - are considered relevant in emotion regulation and hence in the pathophysiology of BD (Syan et al., 2018).

4.1 Differential diagnosis of BD and FTD

The differential diagnosis of mood disorders and bv-FTD remains a challenge (Ducharme et al., 2015; Lanata and Miller, 2016). A combination of cognitive, neuroimaging, as well as genetics analysis is suggested (Ducharme et al., 2015). Executive dysfunction tests provide relative specificity in distinguishing bv-FTD from psychiatric disorders (Elderkin-Thompson et al., 2004). Tests for social cognition and executive dysfunction have been shown to be more sensitive than standard neuropsychological tests for specifically distinguishing bv-FTD cases from controls (Torralva et al., 2009) and also for differentiating bv-FTD from primary psychiatric disorders (Bertoux et al., 2012). Tests offering better specificity for diagnosing bv-FTD include the Social Cognition and Emotional Assessment (Funkiewiez et al., 2012), and the Executive and Social Cognition Battery, especially the Mind in the Eyes (Baron-Cohen et al., 1997) and Faux Pas (Stone et al., 1998). These tests proved better able to differentiate bv-FTD from MDD, even at its earlier stages, possibly because they were initially used to identify early executive and social cognitive impairments (including emotional processing dysfunctions) caused by prefrontal lesions (Gregory et al., 2002; Torralva et al., 2007). However, tools to differentiate bv-FTD from manic states in BD are still lacking (Lanata and Miller, 2016).

Selective neuroimaging evaluation, focusing on frontal and temporal regions using magnetic resonance imaging (MRI) or hypometabolism positron emission transmission (PET), was also tested to improve the differential diagnosis of bvFTD and mood disorders (Ducharme et al., 2015; Panegyres et al., 2007). However, in the initial stages of the disease, these imaging findings may be inconclusive.

Genetic tests for the genes encoding tau (*MAPT*), progranulin (*GRN*), and chromosome 9 open reading frame 72 (*C9ORF72*) are indicated when family history of early onset dementia, or psychosis and mania are reported (Galimberti et al., 2013; Wood et al., 2013). Although the molecular etiology of FTD has not been fully elucidated, the molecular and genetic tools currently indicated for differential diagnosis between bvFTD and primary psychiatric conditions, are based on the knowledge acquired by clinicopathological studies in FTD. This is due to the lack of biological validation corresponding to clinical findings in BD. The scenario reveals the need for further investigation of biological factors that could improve the diagnosis of primary psychiatric diseases.

5. Biological aspects of bipolar disorder and frontotemporal dementia

5.1 Neuropathology of frontotemporal dementia

While the term “frontotemporal dementia” refers to the clinical syndromes, the term “frontotemporal lobar degeneration” (FTLD) describes a heterogeneous group of neurodegenerative diseases that are commonly associated with the clinical syndrome of FTD, and predominant involvement of frontal and temporal lobes (Lowe, 2011; Lowe and Kalaria, 2015; Mackenzie

and Neumann, 2016). Non-specific findings of chronic degeneration, including superficial cortical vacuolization, neuronal loss and gliosis, are observed in affected neocortex of these cases (Cairns et al., 2007; Lowe, 2011). A series of discoveries in the last 15 years has helped redefine our understanding about FTLDs. Although a pathological entity defined as FTLD is based on the abovementioned cortical changes, subcortical degeneration including amygdala, basal ganglia and brainstem is a universal finding (Brettschneider et al., 2013; Cairns et al., 2007; Grinberg et al., 2009). There are three main pathological groups of FTLD based on the most characteristic molecular defect that reflects the underlying pathogenic process (Figure 1).

Figure 1.

Neuropathological classification of frontotemporal lobar degeneration (FTLD), according to molecular findings. Approximately 50% of FTLD cases are TDP-positive and tau-negative (red) while 40% are tau-positive and TDP-negative (yellow). Cases with FET-positive inclusions (tau- and TDP-negative) are estimated to represent 5-10% of FTLD (green). Few cases are ubiquitin-positive without an identified disease-specific protein (grey). Abbreviations: TDP-43, transactive response DNA-binding protein; FET protein Family, fused in sarcoma, Ewing's sarcoma, TATA

In 2006, the transactive response DNA-binding protein (TDP-43) was found to be protein present in the majority of tau-negative FTLD cases with ubiquitin inclusions. FTLD-TDP represents the most common FTLD molecular subtype. Based on the presence of inclusions with distinct morphologies and patterns of cortical laminar distribution, four pathological subtypes of FTLD were recognized with clinical and genetic correlations (Lowe and Kalaria, 2015; Mackenzie and Neumann, 2016). FTLD with tau, a microtubule-

associated protein, is almost as common as the first group, whereas the group with fused in sarcoma DNA-binding protein (FUS) inclusions are quite rare (Cairns et al., 2007; Mackenzie et al., 2011). Studies have shown that the inclusions of most tau and TDP-negative FTLD cases are immunoreactive to antibodies against FUS protein. Recently, studies showed that these FUS-positive inclusions also contain Ewing's sarcoma, TATA-binding protein-associated factor 15 that are collectively known as the FET protein family. In view of these findings, this FTLD subtype is now grouped under the designation of FTLD with FET inclusions (FTLD-FET) (Neumann et al., 2011).

It is important to emphasize that misfolded tau and TDP-43 are not found exclusively in FTLD cases. Aggregates formed by these proteins are also present in other neurodegenerative diseases, such as AD (Josephs et al., 2014; Josephs et al., 2016), chronic traumatic encephalopathy (McKee et al., 2016), argyrophilic grain disease (Rodriguez et al., 2016) and hippocampal sclerosis of aging (Nelson et al., 2011). These protein aggregates are also found in the brains of cognitively normal older adults (Kovacs et al., 2013; Nascimento et al., 2018; Nascimento et al., 2015).

Protein malformation is a process inherent to aging. For example, ubiquitination is a regular mechanism of cell protection indicating that a certain misfolded protein must be degraded, by either proteasome or autophagy pathways (Lilienbaum, 2013; Nedelsky et al., 2008). During aging, the mechanisms of clearance might not suffice to cope with the amount of misfolded proteins that are being produced (Kovacs et al., 2013). The question is, given these proteins are present during normal aging, how do we know the threshold for their aggregates to cause clinical manifestation? The

relationship between the presence of misfolded proteins, clinical manifestations, as well as the molecular pathways by which these protein aggregates lead to neurodegeneration, is not fully understood. Neurodegeneration is caused by a combination of factors, including not only the presence of misfolded proteins, but also synaptic alterations, neuroinflammation (characterized by reactive astrogliosis and activated microglia), and selective neuronal loss (Soto and Estrada, 2008).

Strong clinicopathological associations are observed in topographic distribution of protein aggregates in the brain. These observations led to the proposal of neuropathological staging models for different neurodegenerative disease (Braak and Braak, 1991; Brettschneider et al., 2013; Josephs et al., 2014; Josephs et al., 2016). The relationship between the presence of misfolded proteins and cell death in neurodegenerative diseases was further investigated in AD, but to a lesser degree in FTD patients. It was initially hypothesized that neuronal loss was the problem in neurodegeneration. Indeed, some observations in post-mortem brains corroborated this hypothesis (Anderson et al., 2000; Kimura et al., 2010; Lassmann et al., 1995; Selznick et al., 1999; Su et al., 2000). However, further studies failed to reproduce the same findings and synaptic dysfunctions showed better temporal and topographic correlation with clinical symptoms (Haass and Selkoe, 2007).

One of the theories in neurodegeneration holds that misfolding and aggregation result in the acquisition of a neurotoxic function by the misfolded proteins. Different pathways may operate depending on where the proteins accumulate, i.e. which cell type, cellular compartments (intracellularly or

extracellularly) or brain region (Soto, 2003; Soto and Estrada, 2008). Because cell types and brain regions are affected differently in neurodegenerative diseases, it is unlikely that the same molecular mechanisms underlying AD would explain what occurs in FTD.

In FTD, besides gain of toxic function, loss of function may also play a role. Genetically modified animals (i.e. with mutations in the genes encoding these misfolded proteins e.g. TDP-43) provide a model of loss of function, and have significantly greater cognitive impairment compared to wild-type animals (Caccamo et al., 2012; Tsai et al., 2010). Interestingly, a transgenic mice model mimicking pathological FTLD showed impairment in protein degradation pathways (Caccamo et al., 2015), and therapeutic strategies designed to improve protein quality control mechanisms were able to restore learning/memory impairment (Shahheydari et al., 2017). TDP-43 aggregates are the most common forms of neuropathological abnormalities in FTD, and animal models with mutation in the gene encoding this protein (*TARDBP*) are important tools to help understand the role of this protein in behavioral symptoms of FTD. TDP-43 was found to co-aggregate with the disrupted in schizophrenia 1 (DISC1) protein in the cytosol of neurons in brains of both FTLD mouse models and patients (Endo et al., 2018). Examination of the animal data revealed that co-aggregation of TDP-43/DISC1 reduced synaptic protein expression by disrupting activity-dependent dendritic local translation. As a result, mutated animals showed TDP-43 aggregation, synaptic dysfunction and behavioral deficits. Because these findings were verified *in vivo*, the evidence suggests that TDP-43 participates in the regulation of local translation, which, in turn, affects aberrant behaviors that are relevant to

psychiatric symptoms. Ultimately, this data connects the presence of misfolded TDP-43 with behavioral symptoms.

5.2 Neuropathology of bipolar disorder

Neuropathological abnormalities have also been described in postmortem samples from brains of BD patients. Cortical thinning is observed mainly in temporal, frontal, orbitofrontal and pre-frontal cortices (Elvsashagen et al., 2013; Hanford et al., 2016; Maller et al., 2014; Rimol et al., 2010). Glial deficits, thinning of grey matter in the anterior cingulate, reduced density of neurons in some layers of dorsolateral prefrontal cortex were significant on meta-analysis (Harrison et al., 2018). However, the conclusion of the study was that the data published to date has insufficient robustness, magnitude or specificity to be of clinical or diagnostic value. This is due to the small sample sizes in neuropathological studies. Hundreds of brains are included in genetic studies yet neuropathological research lacks this support. The presence of misfolded proteins in postmortem brains of BD patients has not been consistently explored. Only three studies have analyzed the presence of tau and TDP-43 abnormal aggregates in BD patients (Shioya et al., 2015; Velakoulis et al., 2009a; Velakoulis et al., 2009b). However, these studies involved only small samples of individuals with BD (Table 1). This may be because there are few brain banks worldwide comprising tissue from psychiatric subjects, particularly BD (de Oliveira et al., 2012). One of these studies analyzed abnormal distribution of TDP-43 in patients with late-onset psychosis, including nine patients with SQZ and three with BD. The authors found an absence of normal nuclear staining of TDP-43, without presence of protein inclusions, in three subjects, one of which was diagnosed with BD type

I. Also, the alterations were associated with a positive family history of psychiatric illnesses (Velakoulis et al., 2009a). Another study by the same group focused on analyzing TDP-43 aggregates in postmortem brain of younger-onset FTD subjects. Retrospective analysis of patient clinical files revealed that a subset of these cases was initially diagnosed as having a psychiatric disorder, including one bipolar and four schizophrenic diagnoses. All five patients that had been previously diagnosed with a psychiatric disorder tested positive for misfolded TDP-43. The third study investigated the presence of a tauopathy called argyrophilic grain disease (AGD) in BD subjects. The incidence and extent of AGD pathology seemed to be more severe in the BD group compared to controls, although the low number of BD cases (n=11 versus n=1240 controls) precluded further statistical analyses (Shioya et al., 2015).

Tables

Table 1.

Published studies on frontotemporal lobar degeneration (FTLD) neuropathological alterations in post-mortem brain of BD subjects (n=3).

Author, year	Sample size (n)	Psychiatric cases (n)	Psychiatric cases with TDP-43 (n)	Psychiatric cases with tauopathy (n)	BD with TDP-43	BD with tauopathy	Brain regions analyzed	Main findings
Velakoulis et al., 2009a	23	3	3	n/a	1	n/a	HIP	TDP-43 proteinopathy in one bipolar and two schizophrenic patients
Velakoulis et al., 2009b	17	5	5	n/a	1	n/a	SFG and HIP	Patients with young-onset frontotemporal dementia may be diagnosed with a psychotic illness years before the dementia diagnoses.
Shioya et al., 2015	1251	11	n/a	11	n/a	11	FC, TC, PC, OCC, HIP, AMYG, MO, pons, MB, CB, THA, BNM	All 11 BD patients exhibited argyrophilic grain alterations, a type of tauopathy

BD= bipolar disorder; n/a = not available; HIP= hippocampus; SFG= superior frontal gyrus; FC= frontal cortex; TC= temporal cortex; PC= parietal cortex; OCC= occipital cortex; AMYG= amygdala; MO= medulla oblongata; MB= midbrain; CB= cerebellum; THA= thalamus, BNM= basal nucleus of Meynert.

Other studies have investigated the presence of misfolded proteins in post-mortem brains from patients with psychiatric symptoms. The first was published in 2010 and comprised 72 schizophrenics and 11 schizophrenics with an additional affective component (depression or bipolar disorder) (Geser et al., 2010). The authors found no associations between the control and mental disorder groups. By contrast, a recent study investigated patients with a clinical history of AD together with psychosis and found that the presence of abnormal aggregates of TDP-43 in the hippocampus was associated with a tendency for a reduced likelihood of psychosis (Vatsavayi et al., 2014). These findings contradict results of a study showing TDP-43 neuropathological alterations in patients with psychiatric conditions (Velakoulis et al., 2009a). This could be because different pathways related to these neuropathological alterations may be disrupted across psychiatric and neurological conditions.

Taken together, the study of protein aggregates in psychiatric disorders may indicate that neuropathological findings of TDP-43 and tau are not well-structured characteristics of these conditions. The presence of these protein aggregates in BD may, for example, represent a clinical misdiagnosis in life or an overlap between BD and bv-FTD. In addition, since these neuropathological changes occur during the aging process (Kovacs et al., 2013; Nascimento et al., 2018), the presence of misfolded proteins in the brains of older adults with psychiatric conditions can also be expected. To better address these questions, a detailed and well-structured neuropathological investigation of TDP-43 and tau protein aggregates in the brain of subjects with BD, and with other psychiatric conditions, comparing these with age-matched non-psychiatric subjects is needed. This same study

design could also be employed for an investigation of protein levels (of TDP-43 or tau) in postmortem brain or blood samples of psychiatric cases.

Clarification of the role of these proteins will further understanding of the biological mechanisms underlying psychiatric and cognitive symptoms in mental disorders.

5.3 Molecular genetic studies in frontotemporal dementia

FTD has an important genetic component, since a substantial percentage of cases (30 to 50%) have at least one first-degree relative with FTD and about 10 to 15% have a family history of FTD with autosomal dominant pattern of inheritance (Goldman et al., 2005; Rohrer et al., 2009; Takada, 2017; Takada et al., 2016). The most common genetic forms of FTD are due to mutations in the chromosome 9 open reading frame 72 (*C9orf72*), mutation in the microtubule associated protein tau gene (*MAPT*), and the granulin gene (*GRN*) (Galimberti and Scarpini, 2012; Sieben et al., 2012), explaining 17% of the variance in FTD subjects (Sieben et al., 2012). Among these three most common genetic causes, FTD with mutations in *C9orf72* and *GRN* genes have a clinical profile most closely resembling the psychiatric symptoms seen in BD patients (Woollacott and Rohrer, 2016). *GRN* mutations were found to be common in FTD patients presenting personality changes, sexual disinhibition, ritualistic behaviours, and paranoia (Le Ber et al., 2008). Because molecular genetics explains a high percentage of these cases, interest in the study of molecular causes of FTD has increased greatly in the past two decades. Other less common and rare genes have also been linked to monogenic causes of FTD. Table 2 shows the genes, chromosome location and molecular function of genes linked to FTD, including common and rare

genetic causes. Molecular function of all genes was retrieved from the gene bank of The National Center for Biotechnology Information (NCBI, U.S. National Library of Medicine, Bethesda MD, USA). Besides these genes primarily associated with FTD, mutations in presenilin-1, causative of familial AD, have also been associated with a clinical FTD syndrome (Bernardi et al., 2011).

Table 2.

	Symbol	Name	Chromosome location	Molecular function	Findings in BD
Common	C9orf72	Chromosome 9 Open Reading Frame 72	9p21.2	Autophagy and endocytic traffic	yes ^(Meisler et al., 2013)
	MAPT	Microtubule Associated Protein Tau	17q21.31	Microtubule assembly and stability, establishment and maintenance of neuronal polarity	no
	PGRN	Granulin Precursor	17q21.31	Cytokine-like activity, inflammation, wound repair, and tissue remodeling	yes ^(Rubino et al., 2017)
Rare	ANG	Angiogenin	14q11.2	RNA synthesis. Synthesis and triggers the assembly of stress granules (SGs). Vascularization. Angiogenic activity.	no
	TARDBP	TAR DNA Binding Protein	1p36.22	Regulates transcription and splicing, microRNA biogenesis, apoptosis and cell division.	no
	VCP	Valosin Containing Protein	9p13.3	Ubiquitination and endoplasmic reticulum-associated degradation (ERAD), proteasome degradation	no
	UBQLN2	Ubiquilin 2	Xp11.21	Ubiquitin-proteasome system (UPS), autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway.	no
	OPTN	Optineurin	10p13	Maintenance of Golgi complex, membrane trafficking, in exocytosis.	no
	ATXN2	Ataxin 2	12q24.12	Trafficking and endocytic internalization Epidermal Growth Factor Receptor	no
	CHMP2B	Charged Multivesicular Body Protein 2B	3p11.2	Lysosome functioning	no
	TREM2	Triggering Receptor Expressed on Myeloid Cells 2	6p21.1	Immune responses in macrophages and dendritic cells, chronic inflammations	no
	TBK1	NF-kappa-B activator (TANK)-binding kinase 1	12q14.2	Inflammatory responses	no

Symbol, name, chromosome location and molecular functions of the common and rare genes associated with monogenic forms of frontotemporal dementia.

BD= bipolar disorder; p= short arm; q= long arm

Although a high percentage of cases exhibit a monogenic pattern, it is important to note that a substantial number of FTD cases have not been linked to single genetic mutations (Woollacott and Rohrer, 2016). This suggests there are causative genes yet to be discovered, and/or that this FTD subtype might also have a polygenic or oligogenic pattern, characterizing a multifactorial disease, in which environmental conditions may also play a role.

5.4 Molecular genetic studies in bipolar disorder

Molecular genetics of BD has a distinct pattern compared to FTD. Although the role of a genetic component is unarguable in BD and heritability based on twin studies has been estimated at 60% to 80% (Smoller and Finn, 2003), cases do not display a monogenic mendelian inheritance pattern (Gratten et al., 2014; Kerner, 2014). The hypothesis which best explains this scenario is that susceptibility to BD is most likely influenced by many genetic risk factors with small to moderate effect (Gratten et al., 2014; Kerner, 2014), characterizing a polygenic condition.

Wide variation was observed by studies focusing on the association of individual genes in BD (Craddock and Forty, 2006; Hayden and Nurnberger, 2006). However, some findings are consistent across studies. including genes related to neurotransmitter codification or production, such as the genes coding the serotonin transporter (*5-HTT*, *SERT*), tryptophan hydroxylase (*TPH*), catechol-O-methyltransferase (*COMT*), and D-amino acid oxidase activator (*DAOA*) (Anguelova et al., 2003; Cho et al., 2005; Rotondo et al., 2002), genes encoding neurotrophins, such as the brain-derived neurotrophic factor (*BDNF*), and glycogen synthase kinase 3 beta (*GSK3beta*) (Neves-

Pereira et al., 2002; Ortega et al., 2010; Sklar et al., 2002), and genes related to circadian rhythm, including the aryl hydrocarbon receptor nuclear translocator-like (*ARNTL*) and circadian locomotor output cycles kaput (*CLOCK*) (Nievergelt et al., 2006; Shi et al., 2008).

Genome-wide association studies (GWAS) have identified risk factors, such as voltage-gated calcium channel, *CACNA1C* and Ankyrin G node of Ranvier, *ANK3* (Green et al., 2013; Muhleisen et al., 2014). However, slightly lower estimates of genetic risks have been suggested based on family studies and large population cohorts (Wray and Gottesman, 2012).

In this context, bipolar disorder is a complex multifactorial condition in which, besides genetic risk factors, non-genetic risk factors might contribute to manifestation of the disease. For example, alcohol and drug dependence, as well as physical and sexual abuse, are well-established risk factors associated with BD manifestation (Aas et al., 2014).

5.5 Molecular genetic findings common to bipolar disorder and frontotemporal dementia

Genetic molecular findings are important tools for improving diagnosis and treatment of diseases affecting the central nervous system (CNS) (Ghidoni et al., 2012). Since biopsy in the CNS is highly invasive, the relationship between genetic mutations and peripheral measurements is an important tool. In the case of FTD, mutation-detection rates of the genes associated with the disease have important implications for genetic counseling and testing in clinical settings (Wood et al., 2013). Plasma and CSF levels of proteins encoded by the genes associated with genetic forms of FTD have been studied as biomarkers. Progranulin, a protein encoded by the

GRN gene, was found to be 3.93 times lower in affected and unaffected *GRN* carriers (Ghidoni et al., 2008; Takada et al., 2016). Furthermore, it was possible to establish a cut-off among mutation carriers with and without FTD clinical symptoms. This suggests that lack of progranulin invariably precedes clinical symptoms. Based on these findings, large-scale screening of levels in carriers with the progranulin mutation could represent a useful, quick and inexpensive approach for monitoring future treatments, since progranulin levels should increase during treatment (Ghidoni et al., 2012). Tau protein, encoded by the *MAPT* gene, has also been investigated as a biomarker of FTD in plasma. Higher levels of plasma tau were found in bv-FTD (1.96 pg/mL SD $\pm$ 1.07) compared to controls (1.67 pg/mL SD $\pm$ 0.50) (Foiani et al., 2018), but its importance as a diagnostic tool has yet to be established. Considering the clinical similarities between BD and FTD, researchers have investigated molecular genetic findings of FTD (Table 2) in patients with BD. Interestingly, two different studies showed that progranulin plasma levels were significantly decreased in BD patients compared to controls (Galimberti et al., 2012; Kittel-Schneider et al., 2014). In line with these results, a recent case-report of an Italian male presenting with late-onset BD that developed into bvFTD over time found that this patient carried the mutation in the *GRN* gene (Rubino et al., 2017). Another case report described a BD proband presenting *C9ORF72* gene expansions. Interestingly, the father also carried the *C9ORF72* expansion and postmortem analysis of the brain confirmed FTLD (Meisler et al., 2013). Studies involving larger samples should be conducted to confirm these initial case-report findings.

6. Shared biological pathways may underlie both BD and FTD

Given the complex polygenic and multifactorial etiology of BD, molecular genetics studies have failed to identify a single gene as the cause of the disorder (Gratten et al., 2014; Kerner, 2014). Therefore, the investigation of downstream biological events, rather than BD genetic etiology, has allowed advances in the understanding of the neurobiology of BD. To date, inflammation, oxidative stress and neurotrophic factors are the three downstream biological changes consistently explored and associated with BD pathophysiology and progression (Muneer, 2016). In Table 3, several clinical characteristics, as well as specific molecules related to the biological pathways fundamental in BD are presented and compared with the same aspects detected in similar studies on FTD. Clinical characteristics included age at onset (Snowden et al., 2002; Yassa et al., 1988), disease duration (Medeiros et al., 2016; Young et al., 2018; Zhang et al., 2017) and progression (Grande et al., 2016; Young et al., 2018). For the molecules, due to the large volume of published data regarding inflammation, oxidative stress, and decreased neurotrophic factors in BD, findings from meta-analytic studies were included (Andreazza et al., 2008; Brown et al., 2014; Fernandes et al., 2015; Ghidoni et al., 2008; Goldsmith et al., 2016; Modabbernia et al., 2013; Rao et al., 2017; Tseng et al., 2016; Wang and Miller, 2018). For BD, original articles retrieved using the following search terms (Atagi et al., 2015; Blasko et al., 2006; Bossu et al., 2011; Galimberti et al., 2012; Galimberti et al., 2008; Galimberti et al., 2009; Hu et al., 2010; Kittel-Schneider et al., 2014; Martinez et al., 2008; Miller et al., 2013; Rainero et al., 2009; Rentzos et al., 2006a; Rentzos et al., 2006b; Ventriglia et al., 2013): “bipolar disorder AND

inflammation”, “bipolar disorder AND oxidative stress”, “bipolar disorder AND neurotrophic factor” were included. The same search strategy was used for FTD, where the word “bipolar disorder” was replaced by “frontotemporal dementia”. For both diseases, findings of studies measuring inflammatory biomarkers and neurotrophic factors in human peripheral tissue or CSF were included (Atagi et al., 2015; Blasko et al., 2006; Bossu et al., 2011; Fernandes et al., 2015; Galimberti et al., 2008; Galimberti et al., 2009; Goldsmith et al., 2016; Hu et al., 2010; Kittel-Schneider et al., 2014; Miller et al., 2013; Modabbernia et al., 2013; Rainero et al., 2009; Rao et al., 2017; Rentzos et al., 2006a; Rentzos et al., 2006b; Tseng et al., 2016; Ventriglia et al., 2013; Wang and Miller, 2018). Concerning oxidative stress markers, investigations measuring these alterations in human post-mortem brains were also included (Andreazza et al., 2008; Brown et al., 2014; Martinez et al., 2008).

Table 3.

Comparison of clinical and biological variables between bipolar disorder and frontotemporal dementia.

	BD	FTD
Age at onset	Peak 20 to 40 (Yassa et al., 1988)	45 to 65 (Snowden et al., 2002)
Duration (years)	3.2 to 10.4 (Medeiros et al., 2016; Zhang et al., 2017)	Average of 6 (Young et al., 2018)
Progression	Varies widely across mood episodes (Grande et al., 2016)	Fast (Young et al., 2018)
Inflammation	Cytokines and Cytokine receptors: IL-1, IL-4, IL-6, IL-10 sIL-2R, IL-1 β , and sIL-2R, sIL-6R (Goldsmith et al., 2016; Wang and Miller, 2018; Modabbernia et al., 2013)	Cytokines: IL-6, IL-11, IL12, IL-15, IL-17, IL-23 (Rentzos et al. 2006; Galimberti et al. 2008; Rainero et al. 2009; Hu et al. 2010; Bossù et al., 2011)
	Chemokines: TNF- α , sTNFR1 (Modabbernia et al, 2013)	Chemokines: TBK1, TNF- α , MCP-1 (Miller et al 2013; Blasko et al. 2006)
	Others: progranulin (Galimberti et al., 2012; Kittel-Schneider et al., 2014)	Others: progranulin, TREM2 (Ghidoni et al., 2008; Atagi et al. 2015)
Neurotrophic factors	BDNF, NGF, IGF-1, NT-3 and NT-4/5 (Fernandes et al., 2015; Tseng et al., 2016; Tu et al., 2016; Rao et al., 2017)	BDNF and NGF (Ventriglia et al. 2013; Blasko et al. 2006; Galimberti et al. 2009)
Oxidative damage	Lipid peroxidation, DNA/RNA damage, and nitric oxide, TBARS (Andreazza et al., 2008; Brown et al., 2014)	Lipoxidation-derived protein damage (Martínez et al. 2008)

BD= bipolar disorder; FDT= frontotemporal dementia; IL= interleukin; sIL-2R= soluble IL-2 receptor; sIL-6R= soluble IL-6 receptor; TNF- α = tumor necrosis factor; sTNFR1- soluble tumor necrosis factor receptor 1; TBK1= tumor necrosis factor (TNF) receptor associated factor NF- κ B activator (TANK)-binding kinase 1; MCP-1= monocyte chemoattractant protein 1; TREM2= triggering receptor expressed on myeloid cells 2; BDNF= brain-derived neurotrophic factor; NGF= nerve growth factor; IGF-1= insulin growth factor 1; NT-4/5= neurotrophin-4/5; NT-3= neurotrophin-3

Inflammation is the widely-recognized condition implicated in BD that has been most explored in FTD. However, we found more isolated findings that were not consistently tested across independent groups. The inflammatory markers found, common to both BD and FTD, were interleukin-6 (IL-6), Tumor Necrosis Factor Alpha (TNF- α) and progranulin. IL-6 and TNF- α were increased in BD (Goldsmith et al., 2016) and FTD compared to controls (Bossu et al., 2011; Rainero et al., 2009). IL-6 is an inflammatory cytokine not only implicated in inflammation and infection responses, but also in the regulation of metabolic, regenerative, and neural processes (Scheller et al., 2011). Interestingly, increased levels of IL-6 are associated with neuroprogression in BD (Jacoby et al., 2016; Wiener et al., 2017). Increased IL-6 levels have also been associated with functional impairment in BD patients (Wiener et al., 2017). In FTD, a specific polymorphism in the promoter of the IL-6 gene (174G>C, substitution of a guanine by a cytosine at position 174) significantly modified scores on the Frontal Assessment Battery, suggesting that this interleukin has a particular effect on the clinical aspects of FTD (Rainero et al., 2009). TNF- α is a key component of neuroinflammation processes and physiologically plays an important role in neural function, such as synaptic plasticity, learning and memory, sleep and food intake (Olmos and Llado, 2014). In patients with BD, TNF- α is considered a trait marker of the disease, since higher levels of this molecule are found not only during mood episodes, but also euthymia (Soczynska et al., 2009). In FTD, TNF- α mediates protein aggregates of TDP-43 (Picher-Martel et al., 2015) and the role of progranulin in the cell (Alquezar et al., 2016; Krabbe et al., 2017).

Mutation in the progranulin gene is a common genetic cause of FTD, leading to decreased progranulin protein levels and accumulation of TDP-43 protein. A decrease in progranulin protein is associated with increased levels of TNF- α (Alquezar et al., 2016; Krabbe et al., 2017). Interestingly, progranulin levels were decreased in both BD and FTD (Galimberti et al., 2012; Ghidoni et al., 2008; Kittel-Schneider et al., 2014). Taken together, these findings suggest that IL-6, TNF- α , and progranulin may be biological markers common to both diseases. Genetic variations in HLA (human leukocyte antigen) genes have also been associated with both BD and FTD, and indicate that HLA-related inflammation mechanisms are also present in both disorders (Broce et al., 2018; Tamouza et al., 2018). Although we found shared inflammatory factors, several interleukins and chemokines have different associations with BD and FTD. In BD, IL-1, IL-beta1, IL-4, IL-10, soluble IL-2 receptor (sIL-2R) and sLL-6R and the soluble tumor necrosis factor receptor 1 (sTNFR1) were identified, while in FTD, IL-11, IL-12, IL-15, IL-17, IL-14 and the chemokines tumor necrosis factor (TNF) receptor-associated factor NF- κ B activator (TANK)-binding kinase 1 (TBK1), monocyte chemoattractant protein 1 (MCP-1) and triggering receptor expressed on myeloid cells 2 (TREM2) were found. This means that specific panels of interleukins and chemokines may be used to distinguish BD and FTD.

Levels of neurotrophic factors have been less explored in peripheral tissue in FTD patients than inflammation markers. However, decreased levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) were found in both BD (Fernandes et al., 2015; Rao et al., 2017) and FTD (Blasko et al., 2006; Ventriglia et al., 2013). The role of BDNF in psychiatric

conditions and neurodegenerative processes has been extensively explored. BDNF is the most investigated and well-characterized neurotrophin and major regulator of synaptic plasticity, neuronal survival and differentiation (Koshimizu et al., 2009). The BDNF Val66Met polymorphism has been suggested as a risk factor for both BD (Li et al., 2016) and FTD (Borroni et al., 2012). Clinically, this polymorphism may influence stress sensitivity trait, personality trait, glucocorticoid-induced corticohippocampal remodeling, and behavioral despair (Notaras et al., 2017; Wei et al., 2017). This would explain why individuals carrying the BDNF Val66Met polymorphism are more susceptible to diseases highly influenced by environmental conditions. At the molecular level, this variant is associated with altered protein intracellular and dendritic trafficking (Chen et al., 2004; Chiaruttini et al., 2009), which could impair synaptic activity. NGF is another neurotrophin of interest in both diseases. Higher NGF levels have been associated with increased anxiety, obsessive-compulsive behavior and more impaired functional status (Salles et al., 2017). In neurodegenerative diseases, higher levels of NGF were associated with increased markers of neurodegeneration (as expressed by the ratio P-tau181/Abeta42). This suggests that NGF could be a potential marker for disease progression in both BD and FTD (Blasko et al., 2006). However, research is lacking on factors that may trigger increased NGF in both diseases. Specific neuroprotective factors, such as neurotrophins 4/5 (NT-4/5) and 3 (NT-3), as well as insulin growth factor 1, found to be decreased only in BD, have not been investigated in FTD.

Meta-analytic studies in BD have focused on oxidative reactive factors, such as thiobarbituric acidic reactive substances and nitric oxide activity, and

on oxidative stress-related damage to macromolecules, such as lipid peroxidation, protein nitration and DNA/RNA damage. Levels of lipid peroxidation, DNA/RNA damage, thiobarbituric acidic reactive substances and nitric oxide were significantly higher in BD patients (Andreazza et al., 2008; Brown et al., 2014). There is little evidence supporting increased lipoxidation-derived protein damage in brain tissue of FTD patients (Martinez et al., 2008). Further research focusing on measuring other types of oxidative stress damage in FTD human brain samples could elucidate new pathways implicated in this disease. In this context, recent evidence, using system biology analysis, has shown that DNA damage, oxidative stress and calcium/cAMP may be homeostasis-associated biomarkers in frontotemporal dementia (Palluzzi et al., 2017). Although in FTD studies of human samples there is little evidence of the same types of OS damage found in BD,, several articles report the implication of oxidative stress in FTD based on animal and cellular models. These models show a direct link between causative mutations of FTD and oxidative stress damage caused by mitochondrial dysfunction (Esteras et al., 2017; Lopez-Gonzalez et al., 2016), a hallmark of BD (Kato, 2017). Mitochondria are not cellular organelles exclusively related to damage in macromolecules and oxidative stress. Recently, research has focused on the role of endoplasmic reticulum stress in psychiatry and neurodegenerative disorders (Bengesser et al., 2016; Hetz and Saxena, 2017). Endoplasmic reticulum stress triggers a signaling reaction known as the unfolded protein response (Hetz and Saxena, 2017). This reaction is an adaptive response to improve protein folding and promote quality control mechanisms and degradative pathways. However, under conditions of

prolonged stress, this adaptive response is insufficient, leading to an accumulation of misfolded proteins and cell death. Aggregation of misfolded protein, as previously discussed here (see subtopics 5.1 and 5.2), is a hallmark characteristic observed in post-mortem brain tissue of FTD subjects (Cairns et al., 2007). Although the contribution of these protein aggregates in the pathophysiology of BD requires further investigation, evidence shows that unfolded protein response plays a role in the neuroprogression of the disease (Pfaffenseller et al., 2014). Besides protein aggregates and neuronal loss, endoplasmic reticulum chronic stress also represses synthesis of synaptic proteins (Hetz and Saxena, 2017). This could explain the link between endoplasmic reticulum stress and behavioral/cognitive symptoms in FTD and BD (Cisse et al., 2017; Trinh et al., 2012).

7. Hypothetical model of molecular mechanisms shared by bipolar disorder and frontotemporal dementia

A factor that might explain this conjunction of cellular alterations, including inflammation, oxidative stress and neurotropic factors, as well as endoplasmic reticulum stress response, is brain aging (Dominguez and Barbagallo, 2016). Brain aging is the main risk factor for the development of dementia (Alzheimer's, 2016). Even in FTD cases with underlying monogenic causes, patients manifest symptoms only later in life (Chare et al., 2014). Biological evidence supports the theory of accelerating aging in BD (Fries et al., 2017; Vasconcelos-Moreno et al., 2017). This evidence includes the association between accelerated epigenetic aging and lower global functioning in BD patients (Fries et al., 2017). The fact that BD is associated with higher risk of dementia in old age supports the accelerating ageing hypothesis in BD. In

addition, BD has been strongly associated with metabolic syndrome (Bai et al., 2016). In Figure 2, we propose a scheme showing how these molecular changes might interact and affect the clinical symptoms of FTD and BD. Evidence-based mechanisms in FTD and BD are highlighted in red and blue, respectively (Figure 2). Bold black arrows represent proposed interactions based on general findings related to both BD and FTD. Interactions among biological mechanisms are hierarchically organized into four categories, as follows: (1) triggers, (2) molecular pathways, (3) related-cellular changes, and (4) downstream clinical changes.

Figure 2. Molecular mechanisms potentially shared by bipolar disorder (BD) and frontotemporal dementia (FTD). Triggers, molecular and cellular changes, as well as downstream clinical changes are labeled in purple as 1, 2, 3 and 4, respectively. Red arrows represent evidence-based mechanisms in FTD, blue arrows evidence-based mechanisms in BD, while evidence-based general findings in both BD and FTD are represented by black arrows. Abbreviations: GRN, progranulin; VCP, vasolin-containing protein; *TARDBP*, transactive response DNA-binding protein; *UBQLN2*, ubiquilin 2; *C9orf72*, chromosome 9

open reading frame 72; TNF- α , tumor necrosis factor; TBK1, tumor necrosis factor (TNF) receptor-associated factor NF- κ B activator (TANK)-binding kinase 1; TREM2, triggering receptor expressed on myeloid cells 2.

Caution is required when interpreting this hypothetical model, for instance, differences in disease progression between FTD and BD should be considered. In the case of FTD, variation in levels of molecules (increased or decreased) would be expected to follow a more rapid progressive pattern, while for BD, it is unclear whether these variations would occur only during mood episodes or follow a progressive pattern, albeit at a slower rate compared to FTD. This would also impact the final consequences in the cascade, where we consistently find the presence of misfolded proteins in FTD (Cairns et al., 2007; Mackenzie et al., 2011), but possibly with a lower burden in BD (Shioya et al., 2015; Velakoulis et al., 2009a). The cause of decreased progranulin levels in BD remains unknown, since monogenic mutations in the *GRN* gene are not associated with this disorder. Also, the trigger of decreased NGF levels in both FTD and BD has yet to be investigated. *C9orf72* gene expansions were found in BD proband, as well as family history of BD (Meisler et al., 2013). However, further investigations should be conducted to better characterize the related downstream molecular alterations.

Currently, research on psychiatric and neurological diseases (specifically dementia) is based on the clinical instruments available for detection of patterns of symptoms in order to classify diseases into a specific group, namely, BD or SZ, and FTD or AD (Association, 2013; Rascovsky et al., 2011). As a consequence, psychiatric and neurological diseases have been treated as separate conditions, not only in research, but also in clinical

settings. However, the high heterogeneity of clinical symptoms observed in psychiatric conditions and dementia syndromes, together with the overlapping symptoms, indicate that clinical data collected through semi-structured interviews alone may not suffice as a proxy for electing the best treatment for patients. In this context, biological factors may be a key aspect for improving the diagnosis and treatment of FTD and BD. Decreased progranulin plasma protein levels in both FTD and BD is one example of how subjects clinically classified into different disease groups can present the same biological aspects (Galimberti et al., 2012; Ghidoni et al., 2008; Kittel-Schneider et al., 2014). Here, we present a hypothetical model showing biological aspects potentially shared by FTD and BD (Figure 2). Future investigation comparing the same molecules (particularly inflammation and neurotrophic factors) in cohorts of bv-FTD and BD patient may promote fresh insights in the treatment and diagnosis of these diseases. We need not only to understand the role of these molecules in each of these diseases by studying the potentially shared mechanisms, but also to discover molecular changes that could differentiate psychiatric conditions from dementia (for instance, types of chemokines). The latter could help in early detection, which is crucial for a better prognosis, especially among pre-senile subjects suffering from behavioral changes.

Acknowledgements

Funding: this work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo [grant number, 2017/07089-8].

References

- Aas, M., Etain, B., Bellivier, F., et al., 2014. Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. *Psychol Med* 44, 1653-1662.10.1017/S0033291713002316
- Alquezar, C., de la Encarnacion, A., Moreno, F., et al., 2016. Progranulin deficiency induces overactivation of WNT5A expression via TNF- α /NF- κ B pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers. *J Psychiatry Neurosci* 41, 225-239
- Alzheimer's, A., 2016. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement* 12, 459-509
- Anderson, A.J., Stoltzner, S., Lai, F., et al., 2000. Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. *Neurobiol Aging* 21, 511-524
- Andreazza, A.C., Kauer-Sant'anna, M., Frey, B.N., et al., 2008. Oxidative stress markers in bipolar disorder: a meta-analysis. *J Affect Disord* 111, 135-144.10.1016/j.jad.2008.04.013
- Anguelova, M., Benkelfat, C., Turecki, G., 2003. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. *Mol Psychiatry* 8, 646-653.10.1038/sj.mp.4001336
- Aprahamian, I., Ladeira, R.B., Diniz, B.S., et al., 2014. Cognitive impairment in euthymic older adults with bipolar disorder: a controlled study using cognitive screening tests. *Am J Geriatr Psychiatry* 22, 389-397.10.1016/j.jagp.2012.08.013
- Arts, B., Jabben, N., Krabbendam, L., et al., 2008. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. *Psychol Med* 38, 771-785.10.1017/S0033291707001675
- Association, A.P., 2013. Cautionary statement for forensic use of DSM-5, Diagnostic and statistical manual of mental disorders 5th ed. American Psychiatric Association, Washington, DC.
- Atagi, Y., Liu, C.C., Painter, M.M., et al., 2015. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). *J Biol Chem* 290, 26043-26050.10.1074/jbc.M115.679043
- Bai, Y.M., Li, C.T., Tsai, S.J., et al., 2016. Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder. *BMC Psychiatry* 16, 448.10.1186/s12888-016-1143-8
- Balanza-Martinez, V., Selva, G., Martinez-Aran, A., et al., 2010. Neurocognition in bipolar disorders--a closer look at comorbidities and medications. *Eur J Pharmacol* 626, 87-96.10.1016/j.ejphar.2009.10.018
- Baron-Cohen, S., Jolliffe, T., Mortimore, C., et al., 1997. Another advanced test of theory of mind: evidence from very high functioning adults with autism or asperger syndrome. *J Child Psychol Psychiatry* 38, 813-822
- Bauer, I.E., Soares, J.C., Sele, S., et al., 2017. The Link between Refractoriness and Neuroprogression in Treatment-Resistant Bipolar Disorder. *Mod Trends Pharmacopsychiatry* 31, 10-26.10.1159/000470803
- Bengesser, S.A., Fuchs, R., Lackner, N., et al., 2016. Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic

Drug Targets in the Unfolded Protein Response Pathway Revisited. *CNS Neurol Disord Drug Targets* 15, 403-413

Berk, M., Kapczinski, F., Andreazza, A.C., et al., 2011. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci Biobehav Rev* 35, 804-817.10.1016/j.neubiorev.2010.10.001

Bernardi, L., Anfossi, M., Gallo, M., et al., 2011. PSEN1 and PRNP gene mutations: co-occurrence makes onset very early in a family with FTD phenotype. *J Alzheimers Dis* 24, 415-419.10.3233/JAD-2011-101890

Bertoux, M., Delavest, M., de Souza, L.C., et al., 2012. Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression. *J Neurol Neurosurg Psychiatry* 83, 411-416.10.1136/jnnp-2011-301849

Blasko, I., Lederer, W., Oberbauer, H., et al., 2006. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. *Dement Geriatr Cogn Disord* 21, 9-15.10.1159/000089137

Bora, E., Fornito, A., Yucel, M., et al., 2010. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. *Biol Psychiatry* 67, 1097-1105.10.1016/j.biopsych.2010.01.020

Bora, E., Yucel, M., Pantelis, C., 2009. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord* 113, 1-20.10.1016/j.jad.2008.06.009

Borroni, B., Bianchi, M., Premi, E., et al., 2012. The brain-derived neurotrophic factor Val66Met polymorphism is associated with reduced hippocampus perfusion in frontotemporal lobar degeneration. *J Alzheimers Dis* 31, 243-251.10.3233/JAD-2012-120226

Bossu, P., Salani, F., Alberici, A., et al., 2011. Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. *J Neuroinflammation* 8, 65.10.1186/1742-2094-8-65

Bourne, C., Aydemir, O., Balanza-Martinez, V., et al., 2013. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand* 128, 149-162.10.1111/acps.12133

Braak, H., Braak, E., 1991. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82, 239-259

Brettschneider, J., Del Tredici, K., Toledo, J.B., et al., 2013. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* 74, 20-38.10.1002/ana.23937

Broce, I., Karch, C.M., Wen, N., et al., 2018. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. *PLoS Med* 15, e1002487.10.1371/journal.pmed.1002487

Brown, N.C., Andreazza, A.C., Young, L.T., 2014. An updated meta-analysis of oxidative stress markers in bipolar disorder. *Psychiatry Res* 218, 61-68.10.1016/j.psychres.2014.04.005

Burdick, K.E., Goldberg, J.F., Harrow, M., 2010. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at

15-year follow-up. *Acta Psychiatr Scand* 122, 499-506.10.1111/j.1600-0447.2010.01590.x

Burdick, K.E., Ketter, T.A., Goldberg, J.F., et al., 2015. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. *J Clin Psychiatry* 76, e342-350.10.4088/JCP.14cs09399

Caccamo, A., Majumder, S., Oddo, S., 2012. Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. *Am J Pathol* 180, 293-302.10.1016/j.ajpath.2011.09.022

Caccamo, A., Shaw, D.M., Guarino, F., et al., 2015. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. *Hum Mol Genet* 24, 4625-4635.10.1093/hmg/ddv193

Cairns, N.J., Bigio, E.H., Mackenzie, I.R., et al., 2007. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol* 114, 5-22.10.1007/s00401-007-0237-2

Cao, B., Passos, I.C., Mwangi, B., et al., 2016. Hippocampal volume and verbal memory performance in late-stage bipolar disorder. *J Psychiatr Res* 73, 102-107.10.1016/j.jpsychires.2015.12.012

Chare, L., Hodges, J.R., Leyton, C.E., et al., 2014. New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. *J Neurol Neurosurg Psychiatry* 85, 865-870.10.1136/jnnp-2013-306948

Chen, Z.Y., Patel, P.D., Sant, G., et al., 2004. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. *J Neurosci* 24, 4401-4411.10.1523/JNEUROSCI.0348-04.2004

Chiaruttini, C., Vicario, A., Li, Z., et al., 2009. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. *Proc Natl Acad Sci U S A* 106, 16481-16486.10.1073/pnas.0902833106

Cho, H.J., Meira-Lima, I., Cordeiro, Q., et al., 2005. Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. *Mol Psychiatry* 10, 771-781.10.1038/sj.mp.4001663

Choi, S.S.W., Budhathoki, C., Gitlin, L.N., 2017. Co-Occurrence and Predictors of Three Commonly Occurring Behavioral Symptoms in Dementia: Agitation, Aggression, and Rejection of Care. *Am J Geriatr Psychiatry* 25, 459-468.10.1016/j.jagp.2016.10.013

Cisse, M., Duplan, E., Lorivel, T., et al., 2017. The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. *Mol Psychiatry* 22, 1562-1575.10.1038/mp.2016.152

Craddock, N., Forty, L., 2006. Genetics of affective (mood) disorders. *Eur J Hum Genet* 14, 660-668.10.1038/sj.ejhg.5201549

Cullen, B., Smith, D.J., Deary, I.J., et al., 2017. The 'cognitive footprint' of psychiatric and neurological conditions: cross-sectional study in the UK Biobank cohort. *Acta Psychiatr Scand* 135, 593-605.10.1111/acps.12733

Cullen, B., Ward, J., Graham, N.A., et al., 2016. Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: A systematic review. *J Affect Disord* 205, 165-181.10.1016/j.jad.2016.06.063

Cunha, A.B., Frey, B.N., Andreazza, A.C., et al., 2006. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. *Neurosci Lett* 398, 215-219.10.1016/j.neulet.2005.12.085

Daglas, R., Yucel, M., Cotton, S., et al., 2015. Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. *Int J Bipolar Disord* 3, 9.10.1186/s40345-015-0024-2

de Oliveira, K.C., Nery, F.G., Ferreti, R.E., et al., 2012. Brazilian psychiatric brain bank: a new contribution tool to network studies. *Cell Tissue Bank* 13, 315-326.10.1007/s10561-011-9258-0

Diniz, B.S., Teixeira, A.L., Cao, F., et al., 2017. History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis. *Am J Geriatr Psychiatry* 25, 357-362.10.1016/j.jagp.2016.11.014

Dols, A., Krudop, W., Moller, C., et al., 2016. Late life bipolar disorder evolving into frontotemporal dementia mimic. *Neuropsychiatric disease and treatment* 12, 2207-2212.10.2147/NDT.S99229

Dominguez, L.J., Barbagallo, M., 2016. The biology of the metabolic syndrome and aging. *Curr Opin Clin Nutr Metab Care* 19, 5-11.10.1097/MCO.0000000000000243

Ducharme, S., Price, B.H., Larvie, M., et al., 2015. Clinical Approach to the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. *Am J Psychiatry* 172, 827-837.10.1176/appi.ajp.2015.14101248

Duffy, A., Horrocks, J., Doucette, S., et al., 2014. The developmental trajectory of bipolar disorder. *Br J Psychiatry* 204, 122-128.10.1192/bjp.bp.113.126706

Elderkin-Thompson, V., Boone, K.B., Hwang, S., et al., 2004. Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder. *J Int Neuropsychol Soc* 10, 753-771.10.1017/S1355617704105067

Elshahawi, H.H., Essawi, H., Rabie, M.A., et al., 2011. Cognitive functions among euthymic bipolar I patients after a single manic episode versus recurrent episodes. *J Affect Disord* 130, 180-191.10.1016/j.jad.2010.10.027

Elvsashagen, T., Westlye, L.T., Boen, E., et al., 2013. Bipolar II disorder is associated with thinning of prefrontal and temporal cortices involved in affect regulation. *Bipolar Disord* 15, 855-864.10.1111/bdi.12117

Endo, R., Takashima, N., Nekooki-Machida, Y., et al., 2018. TAR DNA-Binding Protein 43 and Disrupted in Schizophrenia 1 Coaggregation Disrupts Dendritic Local Translation and Mental Function in Frontotemporal Lobar Degeneration. *Biol Psychiatry*.10.1016/j.biopsych.2018.03.008

Esteras, N., Rohrer, J.D., Hardy, J., et al., 2017. Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. *Redox Biol* 12, 410-422.10.1016/j.redox.2017.03.008

Fernandes, B.S., Gama, C.S., Cereser, K.M., et al., 2011. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. *J Psychiatr Res* 45, 995-1004.10.1016/j.jpsychires.2011.03.002

Fernandes, B.S., Molendijk, M.L., Kohler, C.A., et al., 2015. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. *BMC Med* 13, 289.10.1186/s12916-015-0529-7

Foiani, M.S., Woollacott, I.O., Heller, C., et al., 2018. Plasma tau is increased in frontotemporal dementia. *J Neurol Neurosurg Psychiatry*.10.1136/jnnp-2017-317260

Forlenza, O.V., Aghamian, I., Radanovic, M., et al., 2016. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. *Bipolar Disord* 18, 63-70.10.1111/bdi.12360

Fries, G.R., Bauer, I.E., Scaini, G., et al., 2017. Accelerated epigenetic aging and mitochondrial DNA copy number in bipolar disorder. *Transl Psychiatry* 7, 1283.10.1038/s41398-017-0048-8

Funkiewiez, A., Bertoux, M., de Souza, L.C., et al., 2012. The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. *Neuropsychology* 26, 81-90.10.1037/a0025318

Galimberti, D., Dell'Osso, B., Fenoglio, C., et al., 2012. Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. *PLoS One* 7, e32164.10.1371/journal.pone.0032164

Galimberti, D., Fenoglio, C., Serpente, M., et al., 2013. Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. *Biol Psychiatry* 74, 384-391.10.1016/j.biopsych.2013.01.031

Galimberti, D., Scarpini, E., 2012. Genetics of frontotemporal lobar degeneration. *Front Neurol* 3, 52.10.3389/fneur.2012.00052

Galimberti, D., Venturelli, E., Fenoglio, C., et al., 2008. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. *J Neurol* 255, 539-544.10.1007/s00415-008-0737-6

Galimberti, D., Venturelli, E., Villa, C., et al., 2009. MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels. *J Alzheimers Dis* 17, 125-133.10.3233/JAD-2009-1019

Geser, F., Robinson, J.L., Malunda, J.A., et al., 2010. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. *Arch Neurol* 67, 1238-1250.10.1001/archneurol.2010.254

Ghidoni, R., Benussi, L., Glionna, M., et al., 2008. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. *Neurology* 71, 1235-1239.10.1212/01.wnl.0000325058.10218.fc

Ghidoni, R., Paterlini, A., Benussi, L., 2012. Circulating progranulin as a biomarker for neurodegenerative diseases. *Am J Neurodegener Dis* 1, 180-190

Gigante, A.D., Young, L.T., Yatham, L.N., et al., 2011. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. *Int J Neuropsychopharmacol* 14, 1075-1089.10.1017/S146114571000146X

Gildengers, A.G., Butters, M.A., Chisholm, D., et al., 2007. Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. *Am J Geriatr Psychiatry* 15, 174-179.10.1097/JGP.0b013e31802dd367

Goldman, J.S., Farmer, J.M., Wood, E.M., et al., 2005. Comparison of family histories in FTLT subtypes and related tauopathies. *Neurology* 65, 1817-1819.10.1212/01.wnl.0000187068.92184.63

Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 21, 1696-1709.10.1038/mp.2016.3

Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., et al., 2011. Classification of primary progressive aphasia and its variants. *Neurology* 76, 1006-1014.WNL.0b013e31821103e6

Grande, I., Berk, M., Birmaher, B., et al., 2016. Bipolar disorder. *Lancet* 387, 1561-1572.10.1016/S0140-6736(15)00241-X

Gratten, J., Wray, N.R., Keller, M.C., et al., 2014. Large-scale genomics unveils the genetic architecture of psychiatric disorders. *Nat Neurosci* 17, 782-790.10.1038/nn.3708

Green, E.K., Hamshere, M., Forty, L., et al., 2013. Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. *Mol Psychiatry* 18, 1302-1307.10.1038/mp.2012.142

Gregory, C., Lough, S., Stone, V., et al., 2002. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications. *Brain* 125, 752-764

Grinberg, L.T., Rub, U., Ferretti, R.E., et al., 2009. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? *Neuropathol Appl Neurobiol* 35, 406-416.10.1111/j.1365-2990.2009.00997.x

Haass, C., Selkoe, D.J., 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 8, 101-112.10.1038/nrm2101

Hajek, T., Calkin, C., Blagdon, R., et al., 2014. Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. *Neuropsychopharmacology* 39, 2910-2918.10.1038/npp.2014.148

Hall, D., Finger, E.C., 2015. Psychotic symptoms in frontotemporal dementia. *Curr Neurol Neurosci Rep* 15, 46.10.1007/s11910-015-0567-8

Hanford, L.C., Nazarov, A., Hall, G.B., et al., 2016. Cortical thickness in bipolar disorder: a systematic review. *Bipolar Disord* 18, 4-18.10.1111/bdi.12362

Harrison, P.J., Colbourne, L., Harrison, C.H., 2018. The neuropathology of bipolar disorder: systematic review and meta-analysis. *Mol Psychiatry*.10.1038/s41380-018-0213-3

Hayden, E.P., Nurnberger, J.I., Jr., 2006. Molecular genetics of bipolar disorder. *Genes Brain Behav* 5, 85-95.10.1111/j.1601-183X.2005.00138.x

Hetz, C., Saxena, S., 2017. ER stress and the unfolded protein response in neurodegeneration. *Nat Rev Neurol* 13, 477-491.10.1038/nrneurol.2017.99

Hu, W.T., Chen-Plotkin, A., Grossman, M., et al., 2010. Novel CSF biomarkers for frontotemporal lobar degenerations. *Neurology* 75, 2079-2086.10.1212/WNL.0b013e318200d78d

Jacoby, A.S., Munkholm, K., Vinberg, M., et al., 2016. Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder - Results from a prospective study. *J Affect Disord* 197, 167-174.10.1016/j.jad.2016.03.040

Josephs, K.A., Murray, M.E., Whitwell, J.L., et al., 2014. Staging TDP-43 pathology in Alzheimer's disease. *Acta Neuropathol* 127, 441-450.10.1007/s00401-013-1211-9

Josephs, K.A., Murray, M.E., Whitwell, J.L., et al., 2016. Updated TDP-43 in Alzheimer's disease staging scheme. *Acta Neuropathol* 131, 571-585.10.1007/s00401-016-1537-1

Kapczinski, F., Dal-Pizzol, F., Teixeira, A.L., et al., 2010. A systemic toxicity index developed to assess peripheral changes in mood episodes. *Mol Psychiatry* 15, 784-786.10.1038/mp.2009.112

Kapczinski, F., Frey, B.N., Kauer-Sant'Anna, M., et al., 2008. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. *Expert Rev Neurother* 8, 1101-1113.10.1586/14737175.8.7.1101

Kapczinski, F., Magalhaes, P.V., Balanza-Martinez, V., et al., 2014. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. *Acta Psychiatr Scand* 130, 354-363.10.1111/acps.12305

Kato, T., 2017. Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond. *Schizophr Res* 187, 62-66.10.1016/j.schres.2016.10.037

Kerner, B., 2014. Genetics of bipolar disorder. *Appl Clin Genet* 7, 33-42.10.2147/TACG.S39297

Kerr, D.S., Stella, F., Radanovic, M., et al., 2016. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder. *Bipolar Disord* 18, 71-77.10.1111/bdi.12367

Kerstein, A.H., Schroeder, R.W., Baade, L.E., et al., 2013. Frontotemporal dementia mimicking bipolar disorder. *J Psychiatr Pract* 19, 498-500.10.1097/01.pra.0000438190.04786.16

Kessin, L.V., Andersen, P.K., 2004. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? *J Neurol Neurosurg Psychiatry* 75, 1662-1666.10.1136/jnnp.2003.031773

Kimura, T., Fukuda, T., Sahara, N., et al., 2010. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. *J Biol Chem* 285, 38692-38699.10.1074/jbc.M110.136630

Kittel-Schneider, S., Weigl, J., Volkert, J., et al., 2014. Further evidence for plasma progranulin as a biomarker in bipolar disorder. *J Affect Disord* 157, 87-91.10.1016/j.jad.2014.01.006

Koshimizu, H., Kiyosue, K., Hara, T., et al., 2009. Multiple functions of precursor BDNF to CNS neurons: negative regulation of neurite growth, spine formation and cell survival. *Mol Brain* 2, 27.10.1186/1756-6606-2-27

Kovacs, G.G., Milenkovic, I., Wohrer, A., et al., 2013. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. *Acta Neuropathol* 126, 365-384.10.1007/s00401-013-1157-y

Krabbe, G., Minami, S.S., Etchegaray, J.I., et al., 2017. Microglial NFkappaB-TNFalpha hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. *Proc Natl Acad Sci U S A* 114, 5029-5034.10.1073/pnas.1700477114

Lanata, S.C., Miller, B.L., 2016. The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry. *J Neurol Neurosurg Psychiatry* 87, 501-511.10.1136/jnnp-2015-310697

Lancot, K.L., Amatniek, J., Ancoli-Israel, S., et al., 2017. Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. *Alzheimers Dement (N Y)* 3, 440-449.10.1016/j.trci.2017.07.001

Landqvist Waldo, M., Gustafson, L., Nilsson, K., et al., 2013. Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics. *Am J Neurodegener Dis* 2, 276-286

Lassmann, H., Bancher, C., Breitschopf, H., et al., 1995. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. *Acta Neuropathol* 89, 35-41

Le Ber, I., Camuzat, A., Hannequin, D., et al., 2008. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. *Brain* 131, 732-746.10.1093/brain/awn012

Lee, R.S., Hermens, D.F., Scott, J., et al., 2014. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. *J Psychiatr Res* 57, 1-11.10.1016/j.jpsychires.2014.06.019

Leger, G.C., Banks, S.J., 2014. Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia. *Dement Geriatr Cogn Disord* 37, 104-112.10.1159/000354368

Li, M., Chang, H., Xiao, X., 2016. BDNF Val66Met polymorphism and bipolar disorder in European populations: A risk association in case-control, family-based and GWAS studies. *Neurosci Biobehav Rev* 68, 218-233.10.1016/j.neubiorev.2016.05.031

Lilienbaum, A., 2013. Relationship between the proteasomal system and autophagy. *Int J Biochem Mol Biol* 4, 1-26

Lin, A., Reniers, R.L., Wood, S.J., 2013. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. *Br J Psychiatry Suppl* 54, s11-17.10.1192/bjp.bp.112.119156

Liscic, R.M., Storandt, M., Cairns, N.J., et al., 2007. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. *Arch Neurol* 64, 535-540.64/4/535

Lopes, R., Fernandes, L., 2012. Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia. *Depress Res Treat* 2012, 275957.10.1155/2012/275957

Lopez-Gonzalez, R., Lu, Y., Gendron, T.F., et al., 2016. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. *Neuron* 92, 383-391.10.1016/j.neuron.2016.09.015

Lowe, J., 2011. Introduction, in: Dickson, D.W., Weller, R.O. (Eds.), *Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders*, second ed. Wiley-Blackwell, pp. 389-392.

Lowe, J., Kalaria, R., 2015. Dementia, *Greenfield's Neuropathology*, ninth ed. CRC Press, pp. 902-929.

MacCabe, J.H., Lambe, M.P., Cnattingius, S., et al., 2010. Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. *Br J Psychiatry* 196, 109-115.10.1192/bjp.bp.108.060368

Mackenzie, I.R., Neumann, M., 2016. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. *J Neurochem* 138 Suppl 1, 54-70.10.1111/jnc.13588

Mackenzie, I.R., Neumann, M., Baborie, A., et al., 2011. A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathol* 122, 111-113.10.1007/s00401-011-0845-8

Magalhaes, P.V., Dodd, S., Nierenberg, A.A., et al., 2012. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Aust N Z J Psychiatry* 46, 1058-1067.10.1177/0004867412460593

Maller, J.J., Thaveenthiran, P., Thomson, R.H., et al., 2014. Volumetric, cortical thickness and white matter integrity alterations in bipolar disorder type I and II. *J Affect Disord* 169, 118-127.10.1016/j.jad.2014.08.016

Mann-Wrobel, M.C., Carreno, J.T., Dickinson, D., 2011. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. *Bipolar Disord* 13, 334-342.10.1111/j.1399-5618.2011.00935.x

Martinez, A., Carmona, M., Portero-Otin, M., et al., 2008. Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. *J Neuropathol Exp Neurol* 67, 1122-1136.10.1097/NEN.0b013e31818e06f3

Martinez-Aran, A., Vieta, E., Colom, F., et al., 2004. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. *Bipolar Disord* 6, 224-232.10.1111/j.1399-5618.2004.00111.x

Masouy, A., Chopard, G., Vandel, P., et al., 2011. Bipolar disorder and dementia: where is the link? *Psychogeriatrics* 11, 60-67.10.1111/j.1479-8301.2010.00348.x

McKee, A.C., Cairns, N.J., Dickson, D.W., et al., 2016. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol* 131, 75-86.10.1007/s00401-015-1515-z

McKhann, G.M., Albert, M.S., Grossman, M., et al., 2001a. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch Neurol* 58, 1803-1809.nsa10000 [pii]

McKhann, G.M., Albert, M.S., Grossman, M., et al., 2001b. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch Neurol* 58, 1803-1809

Medeiros, G.C., Senco, S.B., Lafer, B., et al., 2016. Association between duration of untreated bipolar disorder and clinical outcome: data from a Brazilian sample. *Rev Bras Psiquiatr* 38, 6-10.10.1590/1516-4446-2015-1680

Meisler, M.H., Grant, A.E., Jones, J.M., et al., 2013. C9ORF72 expansion in a family with bipolar disorder. *Bipolar Disord* 15, 326-332.10.1111/bdi.12063

Mendez, M.F., Shapira, J.S., McMurtray, A., et al., 2007. Accuracy of the clinical evaluation for frontotemporal dementia. *Arch Neurol* 64, 830-835.10.1001/archneur.64.6.830

Miller, B.L., Darby, A.L., Swartz, J.R., et al., 1995. Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. *Dementia* 6, 195-199

Miller, Z.A., Rankin, K.P., Graff-Radford, N.R., et al., 2013. TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J Neurol Neurosurg Psychiatry* 84, 956-962.10.1136/jnnp-2012-304644

Modabbernia, A., Taslimi, S., Brietzke, E., et al., 2013. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. *Biol Psychiatry* 74, 15-25.10.1016/j.biopsych.2013.01.007

Muhleisen, T.W., Leber, M., Schulze, T.G., et al., 2014. Genome-wide association study reveals two new risk loci for bipolar disorder. *Nat Commun* 5, 3339.10.1038/ncomms4339

Muneer, A., 2016. The Neurobiology of Bipolar Disorder: An Integrated Approach. *Chonnam Med J* 52, 18-37.10.4068/cmj.2016.52.1.18

Nascimento, C., Di Lorenzo Alho, A.T., Bazan Conceicao Amaral, C., et al., 2018. Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. *Neuropathol Appl Neurobiol* 44, 286-297.10.1111/nan.12430

Nascimento, C., Suemoto, C.K., Diehl, R.R., et al., 2015. Higher prevalence of TDP-43 proteinopathy in cognitively normal asians: a clinicopathological study on a multiethnic sample. *Brain Pathology*.10.1111/bpa.12296

Nedelsky, N.B., Todd, P.K., Taylor, J.P., 2008. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. *Biochim Biophys Acta* 1782, 691-699.10.1016/j.bbadis.2008.10.002

Nelson, P.T., Schmitt, F.A., Lin, Y., et al., 2011. Hippocampal sclerosis in advanced age: clinical and pathological features. *Brain* 134, 1506-1518.10.1093/brain/awr053

Nery, F.G., Gigante, A.D., Amaral, J.A., et al., 2016. Serum BDNF levels in unaffected first-degree relatives of patients with bipolar disorder. *Rev Bras Psiquiatr* 38, 197-200.10.1590/1516-4446-2015-1801

Neumann, M., Bentmann, E., Dormann, D., et al., 2011. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. *Brain* 134, 2595-2609.10.1093/brain/awr201

- Neves-Pereira, M., Mundo, E., Muglia, P., et al., 2002. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. *Am J Hum Genet* 71, 651-655.10.1086/342288
- Nievergelt, C.M., Kripke, D.F., Barrett, T.B., et al., 2006. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. *Am J Med Genet B Neuropsychiatr Genet* 141B, 234-241.10.1002/ajmg.b.30252
- Notaras, M., Du, X., Gogos, J., et al., 2017. The BDNF Val66Met polymorphism regulates glucocorticoid-induced corticohippocampal remodeling and behavioral despair. *Transl Psychiatry* 7, e1233.10.1038/tp.2017.205
- Nyatsanza, S., Shetty, T., Gregory, C., et al., 2003. A study of stereotypic behaviours in Alzheimer's disease and frontal and temporal variant frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 74, 1398-1402
- Olmos, G., Llado, J., 2014. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. *Mediators Inflamm* 2014, 861231.10.1155/2014/861231
- Organization, W.H., 2018. <http://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults> (September 2018)
- Ortega, F., Perez-Sen, R., Morente, V., et al., 2010. P2X7, NMDA and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons. *Cell Mol Life Sci* 67, 1723-1733.10.1007/s00018-010-0278-x
- Ospina, L.H., Nitzburg, G.C., Shanahan, M., et al., 2018. Social cognition moderates the relationship between neurocognition and community functioning in bipolar disorder. *J Affect Disord* 235, 7-14.10.1016/j.jad.2018.03.013
- Palluzzi, F., Ferrari, R., Graziano, F., et al., 2017. A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia. *PLoS One* 12, e0185797.10.1371/journal.pone.0185797
- Panegyres, P.K., Graves, A., Frencham, K.A., 2007. The clinical differentiation of fronto-temporal dementia from psychiatric disease. *Neuropsychiatr Dis Treat* 3, 637-645
- Passant, U., Elfgrén, C., Englund, E., et al., 2005. Psychiatric symptoms and their psychosocial consequences in frontotemporal dementia. *Alzheimer Dis Assoc Disord* 19 Suppl 1, S15-18
- Passos, I.C., Mwangi, B., Vieta, E., et al., 2016. Areas of controversy in neuroprogression in bipolar disorder. *Acta Psychiatr Scand* 134, 91-103.10.1111/acps.12581
- Pfaffenseller, B., Wollenhaupt-Aguiar, B., Fries, G.R., et al., 2014. Impaired endoplasmic reticulum stress response in bipolar disorder: cellular evidence of illness progression. *Int J Neuropsychopharmacol* 17, 1453-1463.10.1017/S1461145714000443
- Picher-Martel, V., Dutta, K., Phaneuf, D., et al., 2015. Ubiquitin-2 drives NF-kappaB activity and cytosolic TDP-43 aggregation in neuronal cells. *Mol Brain* 8, 71.10.1186/s13041-015-0162-6

Rainero, I., Rubino, E., Cappa, G., et al., 2009. Pro-inflammatory cytokine genes influence the clinical features of frontotemporal lobar degeneration. *Dement Geriatr Cogn Disord* 27, 543-547.10.1159/000225962

Rao, S., Martinez-Cengotitabengoa, M., Yao, Y., et al., 2017. Peripheral blood nerve growth factor levels in major psychiatric disorders. *J Psychiatr Res* 86, 39-45.10.1016/j.jpsychires.2016.11.012

Rascovsky, K., Hodges, J.R., Knopman, D., et al., 2011. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134, 2456-2477.10.1093/brain/awr179

Rentzos, M., Paraskevas, G.P., Kapaki, E., et al., 2006a. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *J Neurol Sci* 249, 110-114.10.1016/j.jns.2006.05.063

Rentzos, M., Zoga, M., Paraskevas, G.P., et al., 2006b. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *J Geriatr Psychiatry Neurol* 19, 114-117.10.1177/0891988706286226

Rimol, L.M., Hartberg, C.B., Nesvag, R., et al., 2010. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. *Biol Psychiatry* 68, 41-50.10.1016/j.biopsych.2010.03.036

Rise, I.V., Haro, J.M., Gjervan, B., 2016. Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients. *Neuropsychiatr Dis Treat* 12, 1203-1213.10.2147/NDT.S100843

Rodriguez, R.D., Suemoto, C.K., Molina, M., et al., 2016. Argyrophilic Grain Disease: Demographics, Clinical, and Neuropathological Features From a Large Autopsy Study. *J Neuropathol Exp Neurol* 75, 628-635.10.1093/jnen/nlw034

Rohrer, J.D., Guerreiro, R., Vandrovcova, J., et al., 2009. The heritability and genetics of frontotemporal lobar degeneration. *Neurology* 73, 1451-1456.10.1212/WNL.0b013e3181bf997a

Rosa, A.R., Magalhaes, P.V., Czepielewski, L., et al., 2014. Clinical staging in bipolar disorder: focus on cognition and functioning. *J Clin Psychiatry* 75, e450-456.10.4088/JCP.13m08625

Rotondo, A., Mazzanti, C., Dell'Osso, L., et al., 2002. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. *Am J Psychiatry* 159, 23-29.10.1176/appi.ajp.159.1.23

Rubino, E., Vacca, A., Gallone, S., et al., 2017. Late onset bipolar disorder and frontotemporal dementia with mutation in progranulin gene: a case report. *Amyotroph Lateral Scler Frontotemporal Degener*, 1-3.10.1080/21678421.2017.1339716

Salles, F.H., Soares, P.S., Wiener, C.D., et al., 2017. Mental disorders, functional impairment, and nerve growth factor. *Psychol Res Behav Manag* 10, 9-15.10.2147/PRBM.S104814

Scheller, J., Chalaris, A., Schmidt-Arras, D., et al., 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta* 1813, 878-888.10.1016/j.bbamcr.2011.01.034

Schoder, D., Hannequin, D., Martinaud, O., et al., 2010. Morbid risk for schizophrenia in first-degree relatives of people with frontotemporal dementia. *Br J Psychiatry* 197, 28-35.10.1192/bjp.bp.109.068981

Schouws, S.N., Comijs, H.C., Dols, A., et al., 2016. Five-year follow-up of cognitive impairment in older adults with bipolar disorder. *Bipolar Disord* 18, 148-154.10.1111/bdi.12374

Seeley, W.W., 2017. Mapping Neurodegenerative Disease Onset and Progression. *Cold Spring Harb Perspect Biol* 9.10.1101/cshperspect.a023622

Selznick, L.A., Holtzman, D.M., Han, B.H., et al., 1999. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. *J Neuropathol Exp Neurol* 58, 1020-1026

Shahheydari, H., Ragagnin, A., Walker, A.K., et al., 2017. Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. *Front Mol Neurosci* 10, 119.10.3389/fnmol.2017.00119

Shi, J., Wittke-Thompson, J.K., Badner, J.A., et al., 2008. Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. *Am J Med Genet B Neuropsychiatr Genet* 147B, 1047-1055.10.1002/ajmg.b.30714

Shioya, A., Saito, Y., Arima, K., et al., 2015. Neurodegenerative changes in patients with clinical history of bipolar disorders. *Neuropathology* 35, 245-253.10.1111/neup.12191

Sieben, A., Van Langenhove, T., Engelborghs, S., et al., 2012. The genetics and neuropathology of frontotemporal lobar degeneration. *Acta Neuropathol* 124, 353-372.10.1007/s00401-012-1029-x

Sklar, P., Gabriel, S.B., McInnis, M.G., et al., 2002. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor. *Mol Psychiatry* 7, 579-593.10.1038/sj.mp.4001058

Smoller, J.W., Finn, C.T., 2003. Family, twin, and adoption studies of bipolar disorder. *Am J Med Genet C Semin Med Genet* 123C, 48-58.10.1002/ajmg.c.20013

Snowden, J.S., Neary, D., Mann, D.M., 2002. Frontotemporal dementia. *Br J Psychiatry* 180, 140-143

Soczynska, J.K., Kennedy, S.H., Goldstein, B.I., et al., 2009. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? *Neurotoxicology* 30, 497-521.10.1016/j.neuro.2009.03.004

Soto, C., 2003. Unfolding the role of protein misfolding in neurodegenerative diseases. *Nat Rev Neurosci* 4, 49-60.10.1038/nrn1007

Soto, C., Estrada, L.D., 2008. Protein misfolding and neurodegeneration. *Arch Neurol* 65, 184-189.10.1001/archneurol.2007.56

Stone, V.E., Baron-Cohen, S., Knight, R.T., 1998. Frontal lobe contributions to theory of mind. *J Cogn Neurosci* 10, 640-656

Su, J.H., Nichol, K.E., Sitch, T., et al., 2000. DNA damage and activated caspase-3 expression in neurons and astrocytes: evidence for apoptosis in frontotemporal dementia. *Exp Neurol* 163, 9-19.10.1006/exnr.2000.7340

Syan, S.K., Smith, M., Frey, B.N., et al., 2018. Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. *J Psychiatry Neurosci* 43, 170175.10.1503/jpn.170175

Takada, L.T., 2015. The Genetics of Monogenic Frontotemporal Dementia. *Dement Neuropsychol* 9, 219-229.10.1590/1980-57642015DN93000003

Takada, L.T., 2017. Frontotemporal Dementia Neurogenetics, The Human Frontal Lobes, Third ed. Guilford, United States.

Takada, L.T., Bahia, V.S., Guimaraes, H.C., et al., 2016. GRN and MAPT Mutations in 2 Frontotemporal Dementia Research Centers in Brazil. *Alzheimer Dis Assoc Disord* 30, 310-317.10.1097/WAD.0000000000000153

Tamouza, R., Oliveira, J., Etain, B., et al., 2018. HLA genetics in bipolar disorder. *Acta Psychiatr Scand*.10.1111/acps.12912

Tidemalm, D., Haglund, A., Karanti, A., et al., 2014. Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patients. *PLoS One* 9, e94097.10.1371/journal.pone.0094097

Torralva, T., Kipps, C.M., Hodges, J.R., et al., 2007. The relationship between affective decision-making and theory of mind in the frontal variant of fronto-temporal dementia. *Neuropsychologia* 45, 342-349.10.1016/j.neuropsychologia.2006.05.031

Torralva, T., Roca, M., Gleichgerricht, E., et al., 2009. A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia. *Brain* 132, 1299-1309.10.1093/brain/awp041

Torrent, C., Martinez-Aran, A., del Mar Bonnin, C., et al., 2012. Long-term outcome of cognitive impairment in bipolar disorder. *J Clin Psychiatry* 73, e899-905.10.4088/JCP.11m07471

Trinh, M.A., Kaphzan, H., Wek, R.C., et al., 2012. Brain-specific disruption of the eIF2alpha kinase PERK decreases ATF4 expression and impairs behavioral flexibility. *Cell Rep* 1, 676-688.10.1016/j.celrep.2012.04.010

Tsai, K.J., Yang, C.H., Fang, Y.H., et al., 2010. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. *J Exp Med* 207, 1661-1673.10.1084/jem.20092164

Tseng, P.T., Chen, Y.W., Tu, K.Y., et al., 2016. State-dependent increase in the levels of neurotrophin-3 and neurotrophin-4/5 in patients with bipolar disorder: A meta-analysis. *J Psychiatr Res* 79, 86-92.10.1016/j.jpsychires.2016.05.009

Van Rheenen, T.E., Lewandowski, K.E., Tan, E.J., et al., 2017. Characterizing cognitive heterogeneity on the schizophrenia-bipolar disorder spectrum. *Psychol Med* 47, 1848-1864.10.1017/S0033291717000307

Vasconcelos-Moreno, M.P., Fries, G.R., Gubert, C., et al., 2017. Telomere Length, Oxidative Stress, Inflammation and BDNF Levels in Siblings of Patients with Bipolar Disorder: Implications for Accelerated Cellular Aging. *Int J Neuropsychopharmacol* 20, 445-454.10.1093/ijnp/pyx001

Vatsavayi, A.V., Kofler, J., Demichele-Sweet, M.A., et al., 2014. TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. *Int Psychogeriatr* 26, 987-994.10.1017/S1041610214000246

Vavakova, M., Durackova, Z., Trebaticka, J., 2015. Markers of Oxidative Stress and Neuroprogression in Depression Disorder. *Oxid Med Cell Longev* 2015, 898393.10.1155/2015/898393

Velakoulis, D., Walterfang, M., Mocellin, R., et al., 2009a. Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. *Aust N Z J Psychiatry* 43, 739-745.10.1080/00048670903001984

Velakoulis, D., Walterfang, M., Mocellin, R., et al., 2009b. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. *The British journal of psychiatry : the journal of mental science* 194, 298-305.10.1192/bjp.bp.108.057034

Ventriglia, M., Zanardini, R., Bonomini, C., et al., 2013. Serum brain-derived neurotrophic factor levels in different neurological diseases. *Biomed Res Int* 2013, 901082.10.1155/2013/901082

Vieta, E., Popovic, D., Rosa, A.R., et al., 2013. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry* 28, 21-29.10.1016/j.eurpsy.2011.11.007

Vohringer, P.A., Barroilhet, S.A., Amerio, A., et al., 2013. Cognitive impairment in bipolar disorder and schizophrenia: a systematic review. *Front Psychiatry* 4, 87.10.3389/fpsy.2013.00087

Vrabie, M., Marinescu, V., Talasman, A., et al., 2015. Cognitive impairment in manic bipolar patients: important, understated, significant aspects. *Ann Gen Psychiatry* 14, 41.10.1186/s12991-015-0080-0

Wang, A.K., Miller, B.J., 2018. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression. *Schizophr Bull* 44, 75-83.10.1093/schbul/sbx035

Wei, S.M., Eisenberg, D.P., Nabel, K.G., et al., 2017. Brain-Derived Neurotrophic Factor Val66Met Polymorphism Affects the Relationship Between an Anxiety-Related Personality Trait and Resting Regional Cerebral Blood Flow. *Cereb Cortex* 27, 2175-2182.10.1093/cercor/bhw072

Wiener, C.D., Moreira, F.P., Cardoso, T.A., et al., 2017. Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder. *J Neuroimmunol* 307, 33-36.10.1016/j.jneuroim.2017.03.003

Wood, E.M., Falcone, D., Suh, E., et al., 2013. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. *JAMA Neurol* 70, 1411-1417.10.1001/jamaneurol.2013.3956

Woollacott, I.O., Rohrer, J.D., 2016. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *J Neurochem* 138 Suppl 1, 6-31.10.1111/jnc.13654

Woolley, J.D., Khan, B.K., Murthy, N.K., et al., 2011. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. *J Clin Psychiatry* 72, 126-133.10.4088/JCP.10m06382oli

Woolley, J.D., Wilson, M.R., Hung, E., et al., 2007. Frontotemporal dementia and mania. *Am J Psychiatry* 164, 1811-1816.10.1176/appi.ajp.2007.07061001

Wray, N.R., Gottesman, I.I., 2012. Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. *Front Genet* 3, 118.10.3389/fgene.2012.00118

Yassa, R., Nair, V., Nastase, C., et al., 1988. Prevalence of bipolar disorder in a psychogeriatric population. *J Affect Disord* 14, 197-201

Young, J.J., Lavakumar, M., Tampi, D., et al., 2018. Frontotemporal dementia: latest evidence and clinical implications. *Ther Adv Psychopharmacol* 8, 33-48.10.1177/2045125317739818

Zamboni, G., Huey, E.D., Krueger, F., et al., 2008. Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates. *Neurology* 71, 736-742.10.1212/01.wnl.0000324920.96835.95

Zhang, L., Yu, X., Fang, Y.R., et al., 2017. Duration of untreated bipolar disorder: a multicenter study. *Sci Rep* 7, 44811.10.1038/srep44811